Norway Biopharmaceutical Market Size & Outlook, 2026-2033

The biopharmaceutical market in Norway is expected to reach a projected revenue of US$ 8,421.0 million by 2033. A compound annual growth rate of 7% is expected of Norway biopharmaceutical market from 2026 to 2033.
Revenue, 2025 (US$M)
$4,820.7
Forecast, 2033 (US$M)
$8,421.0
CAGR, 2026 - 2033
7%
Report Coverage
Norway

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Norway biopharmaceutical market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Norway biopharmaceutical market highlights

  • The Norway biopharmaceutical market generated a revenue of USD 4,820.7 million in 2025 and is expected to reach USD 8,421.0 million by 2033.
  • The Norway market is expected to grow at a CAGR of 7% from 2026 to 2033.
  • In terms of segment, monoclonal antibody was the largest revenue generating molecule type in 2025.
  • Hormone is the most lucrative molecule type segment registering the fastest growth during the forecast period.


Biopharmaceutical market data book summary

Market revenue in 2025USD 4,820.7 million
Market revenue in 2033USD 8,421.0 million
Growth rate7% (CAGR from 2026 to 2033)
Largest segmentMonoclonal antibody
Fastest growing segmentHormone
Historical data2021 - 2024
Base year2025
Forecast period2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationMonoclonal Antibody, Interferon, Insulin, Growth and Coagulation Factor, Erythropoietin, Vaccine, Hormone
Key market players worldwideF. Hoffmann-La Roche Ltd., Novartis AG ADR, AbbVie Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., Bristol-Myers Squibb Company, Sanofi SA, GSK PLC ADR, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Biogen Inc, Eli Lilly and Company, Novo Nordisk A/S ADR, Amgen Inc.


Other key industry trends

  • In terms of revenue, Norway accounted for 1.0% of the global biopharmaceutical market in 2025.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In Europe, Germany biopharmaceutical market is projected to lead the regional market in terms of revenue in 2033.
  • Spain is the fastest growing regional market in Europe and is projected to reach USD 18,408.6 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Biopharmaceutical Market Companies

Name Profile # Employees HQ Website
Amgen Inc. View profile - - -
Eli Lilly and Company View profile - - -
Merck & Co., Inc. View profile - - -
Johnson & Johnson Services, Inc. View profile - - -
Takeda Pharmaceutical Company Limited View profile - - -
Bristol-Myers Squibb Company View profile - - -
Pfizer Inc. View profile - - -
F. Hoffmann-La Roche Ltd. View profile - - -
AbbVie Inc. View profile - - -
Biogen Inc View profile 7570 225 Binney Street, Cambridge, MA, United States, 02142 https://www.biogen.com
AstraZeneca PLC View profile 89900 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA https://www.astrazeneca.com
Novo Nordisk A/S ADR View profile 66015 Novo Alle 1, Bagsvaerd, Denmark, 2880 https://www.novonordisk.com
GSK PLC ADR View profile 70200 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS https://www.gsk.com
Sanofi SA View profile 87994 46, avenue de la Grande Armée, Paris, France, 75017 https://www.sanofi.com
Novartis AG ADR View profile 76057 Lichtstrasse 35, Basel, Switzerland, 4056 https://www.novartis.com

Norway biopharmaceutical market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical market will help companies and investors design strategic landscapes.


Monoclonal antibody was the largest segment with a revenue share of 69.11% in 2025. Horizon Databook has segmented the Norway biopharmaceutical market based on monoclonal antibody, interferon, insulin, growth and coagulation factor, erythropoietin, vaccine, hormone covering the revenue growth of each sub-segment from 2021 to 2033.


Reasons to subscribe to Norway biopharmaceutical market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Norway biopharmaceutical market databook

  • Our clientele includes a mix of biopharmaceutical market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Norway biopharmaceutical market , including forecasts for subscribers. This country databook contains high-level insights into Norway biopharmaceutical market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Norway biopharmaceutical market size, by molecule type, 2021-2033 (US$M)

Norway Biopharmaceutical Market Outlook Share, 2025 & 2033 (US$M)

Norway biopharmaceutical market size, by molecule type, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online